Cargando…

Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort

Detalles Bibliográficos
Autores principales: Al Arashi, Wala, Iñiguez Ubiaga, Carlota, Hensor, Elizabeth M, Gaffney, Katie, Freeston, Jane, Vandevelde, Claire, Barr, Andrew, van der Horst-Bruinsma, Irene, Marzo-Ortega, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649944/
https://www.ncbi.nlm.nih.gov/pubmed/31433400
http://dx.doi.org/10.1093/rap/rky036
_version_ 1783438078393712640
author Al Arashi, Wala
Iñiguez Ubiaga, Carlota
Hensor, Elizabeth M
Gaffney, Katie
Freeston, Jane
Vandevelde, Claire
Barr, Andrew
van der Horst-Bruinsma, Irene
Marzo-Ortega, Helena
author_facet Al Arashi, Wala
Iñiguez Ubiaga, Carlota
Hensor, Elizabeth M
Gaffney, Katie
Freeston, Jane
Vandevelde, Claire
Barr, Andrew
van der Horst-Bruinsma, Irene
Marzo-Ortega, Helena
author_sort Al Arashi, Wala
collection PubMed
description
format Online
Article
Text
id pubmed-6649944
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-66499442019-08-20 Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort Al Arashi, Wala Iñiguez Ubiaga, Carlota Hensor, Elizabeth M Gaffney, Katie Freeston, Jane Vandevelde, Claire Barr, Andrew van der Horst-Bruinsma, Irene Marzo-Ortega, Helena Rheumatol Adv Pract Letter to the Editor (matters arising from published papers) Oxford University Press 2018-10-18 /pmc/articles/PMC6649944/ /pubmed/31433400 http://dx.doi.org/10.1093/rap/rky036 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Letter to the Editor (matters arising from published papers)
Al Arashi, Wala
Iñiguez Ubiaga, Carlota
Hensor, Elizabeth M
Gaffney, Katie
Freeston, Jane
Vandevelde, Claire
Barr, Andrew
van der Horst-Bruinsma, Irene
Marzo-Ortega, Helena
Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort
title Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort
title_full Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort
title_fullStr Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort
title_full_unstemmed Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort
title_short Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort
title_sort comment on: tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a united kingdom cohort
topic Letter to the Editor (matters arising from published papers)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649944/
https://www.ncbi.nlm.nih.gov/pubmed/31433400
http://dx.doi.org/10.1093/rap/rky036
work_keys_str_mv AT alarashiwala commentontumournecrosisfactorinhibitorsurvivalandpredictorsofresponseinaxialspondyloarthritisfindingsfromaunitedkingdomcohort
AT iniguezubiagacarlota commentontumournecrosisfactorinhibitorsurvivalandpredictorsofresponseinaxialspondyloarthritisfindingsfromaunitedkingdomcohort
AT hensorelizabethm commentontumournecrosisfactorinhibitorsurvivalandpredictorsofresponseinaxialspondyloarthritisfindingsfromaunitedkingdomcohort
AT gaffneykatie commentontumournecrosisfactorinhibitorsurvivalandpredictorsofresponseinaxialspondyloarthritisfindingsfromaunitedkingdomcohort
AT freestonjane commentontumournecrosisfactorinhibitorsurvivalandpredictorsofresponseinaxialspondyloarthritisfindingsfromaunitedkingdomcohort
AT vandeveldeclaire commentontumournecrosisfactorinhibitorsurvivalandpredictorsofresponseinaxialspondyloarthritisfindingsfromaunitedkingdomcohort
AT barrandrew commentontumournecrosisfactorinhibitorsurvivalandpredictorsofresponseinaxialspondyloarthritisfindingsfromaunitedkingdomcohort
AT vanderhorstbruinsmairene commentontumournecrosisfactorinhibitorsurvivalandpredictorsofresponseinaxialspondyloarthritisfindingsfromaunitedkingdomcohort
AT marzoortegahelena commentontumournecrosisfactorinhibitorsurvivalandpredictorsofresponseinaxialspondyloarthritisfindingsfromaunitedkingdomcohort